Cantor Fitzgerald Thinks This Pharma Stock Could Double

The analyst isn't concerned about UBX's trek to record lows

Digital Content Manager
Mar 7, 2019 at 12:55 PM
facebook twitter linkedin


The shares of Unity Biotechnology, Inc. (NASDAQ:UBX) suffered an 11.2% drop yesterday -- and touched a record low of $9.05 -- after poorly received fourth-quarter earnings. Despite all this, Cantor Fitzgerald last night initiated coverage of UBX with an "overweight" rating and a price target of $21 -- more than double the stock's current perch. The analyst waxed optimistic on Unity's "portfolio with multiple blockbusters," citing an increasing market for the company's age-related disease treatments. 

Cantor Fitzgerald is in good company, with three "buy" or better ratings and not a single "sell" for UBX. Plus, the analyst's $21 price target is still lower than the consensus 12-month target of $25.40 -- a roughly 173% premium to current levels. 

The stock was trading around $17 -- its initial public offering (IPO) price -- to start the year, but is down more than 42% year-to-date, amid pressure from its 20-day moving average. However, UBX today is up 2.4% at $9.30. 

UBX Chart March 7

Should Unity Biotechnology extend its bounce from new-low territory, a short squeeze could propel the stock higher. Currently, the 5.16 million UBX shares sold short represent a whopping 20.3% of the stock's available float. It would take over a month to buy back all these pessimistic positions, at the equity's average daily trading volume.
 

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!